New England Biolabs (NEB), a supplier of innovative products tailored for molecular biology research, announced on Thursday that it has achieved recertification as a B Corporation (B Corp).
NEB said that it remains one of the few life-science companies to achieve this certification, which requires for-profit businesses to meet high standards of social and environmental impact.
To become certified, NEB exceeded standards across various areas of governance, including customer stewardship, treatment of employees, environmental protection and community engagement.
LEO Pharma reports positive phase 2b results for temtokibart in atopic dermatitis
New England Biolabs achieves B Corporation recertification
Palatin presents symptom resolution data from Phase 3 dry eye disease trial
BioArctic expands exidavnemab trial to include Multiple System Atrophy patients
NeuroSense Therapeutics completes PrimeC commercial manufacturing scale-up
SCG releases SCG101 late-breaking clinical data in HBV-related hepatocellular carcinoma
Genprex signs new research agreement with University of Pittsburgh to advance diabetes gene therapy
AstraZeneca and Daiichi Sankyo's Enhertu shows strong results in early-stage breast cancer trial